2nd firm agrees to temporary shutdown in outbreak

by Jay Lindsay
This photo provided Oct. 9, 2012, by the Minnesota Department of Health shows shows vials of the injectable steroid product made by New England Compounding Center implicated in a fungal meningitis outbreak that were being shipped to the Centers for Disease Control and Prevention in Atlanta from Minneapolis. About 17,700 single-dose vials of the steroid sent to 23 states have been recalled. The outbreak involves 10 states, including Minnesota. (AP Photo/Minnesota Department of Health)

(AP)—A Massachusetts company run by the same executives who operated a specialty pharmacy linked to a fatal meningitis outbreak has agreed to temporarily shut down for inspection by state and federal regulators.

Ameridose is located in Westborough, Mass. The Compounding Center, which produced a steroid linked to the outbreak, is in Framingham. Both firms are run by Barry Cadden and Greg Conigliaro.

Ameridose provides sterile medication in prefilled oral syringes to about 3,000 hospitals nationwide. It opened its doors in 2006, eight years after NECC opened.

The Massachusetts Department of Public Health says Ameridose agreed to the shutdown until inspections by and the U.S. are completed.

There is no recall of Ameridose products.

The outbreak has sickened 137 people in 10 states. Twelve have died.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Mass. gov: Drug firm may have misled regulators

Oct 10, 2012

(AP)—Massachusetts Gov. Deval Patrick says the specialty pharmacy linked to a deadly meningitis outbreak may have misled regulators and done work beyond the scope of its state license.

US pharmacy linked to outbreak issues wide recall

Oct 07, 2012

(AP)—The pharmacy that distributed a steroid linked to an outbreak of fungal meningitis has issued a voluntary recall of all of its products, calling the move a precautionary measure.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments